Publicacións en colaboración con investigadores/as de Fundación Hospital Alcorcón (30)

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2015

  1. Endocannabinoids and Neurodegenerative disorders: Parkinson’s disease, Huntington’s chorea, Alzheimer’s disease, and others

    Handbook of Experimental Pharmacology (Springer New York LLC), pp. 233-259

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  2. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

2013

  1. Feasibility and safety of hospital discharge 24 hours after laparoscopic radical prostatectomy

    Archivos Espanoles de Urologia, Vol. 66, Núm. 10, pp. 931-938

  2. Resultados oncológicos en pacientes potencialmente candidatos a vigilancia activa sometidos a prostatectomía radical

    Actas Urologicas Espanolas, Vol. 37, Núm. 10, pp. 603-607

  3. Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour

    BJU International, Vol. 111, Núm. 4 B

2011

  1. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized clinical trial with 2-year follow-up

    European Urology, Vol. 60, Núm. 4, pp. 734-739

  2. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

  3. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

2010

  1. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors

    Neurobiology of Disease, Vol. 37, Núm. 2, pp. 434-440

2009

  1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    GLIA, Vol. 57, Núm. 11, pp. 1154-1167

  2. Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study

    Psychiatric Genetics, Vol. 19, Núm. 6, pp. 336

  3. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain, Vol. 132, Núm. 11, pp. 3152-3164

  4. The endocannabinoid system in neuropathological states

    International Review of Psychiatry, Vol. 21, Núm. 2 SPEC. ISS., pp. 172-180

2008

  1. Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa

    Journal of Histochemistry and Cytochemistry, Vol. 56, Núm. 5, pp. 511-516

  2. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance

    Neuroscience, Vol. 153, Núm. 3, pp. 687-699

  3. The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis

    Journal of Biological Chemistry, Vol. 283, Núm. 19, pp. 13320-13324

2007

  1. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

    Trends in Pharmacological Sciences, Vol. 28, Núm. 1, pp. 39-45